FDA urged to expand on integrated review

A new FDA drug review template, part of an integrated review system unveiled in June, is raising concerns that data that would be valuable for drug development and for informing treatment decisions could be left on the cutting room floor.

FDA's integrated review shifts the agency's NDA and BLA review process to

Read the full 515 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE